Evidence map›Paper›PMID 28069896›Full record

ArticleEndocrine connections2017

Anti-tumor effects of shikonin derivatives on human medullary thyroid carcinoma cells.

Carina Hasenoehrl, Gert Schwach, Nassim Ghaffari-Tabrizi-Wizsy, Robert Fuchs, Nadine Kretschmer, Rudolf Bauer, Roswitha Pfragner

Open access · goldAbstract read
In one paragraph

Article in Endocrine connections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Effective paclitaxel:Toxicology research · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Deoxyshikonin isolated fromPharmaceutical biology · 2019
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Carina HasenoehrlInstitute of Pathophysiology and ImmunologyCenter of Molecular Medicine, Medical University of Graz, Graz, Austria.
Gert SchwachInstitute of Pathophysiology and ImmunologyCenter of Molecular Medicine, Medical University of Graz, Graz, Austria.
Nassim Ghaffari-Tabrizi-WizsyInstitute of Pathophysiology and ImmunologyCenter of Molecular Medicine, Medical University of Graz, Graz, Austria.
Robert FuchsInstitute of Pathophysiology and ImmunologyCenter of Molecular Medicine, Medical University of Graz, Graz, Austria.
Nadine KretschmerDepartment of PharmacognosyInstitute of Pharmaceutical Sciences, University of Graz, Graz, Austria.
Rudolf BauerDepartment of PharmacognosyInstitute of Pharmaceutical Sciences, University of Graz, Graz, Austria.
Roswitha PfragnerInstitute of Pathophysiology and ImmunologyCenter of Molecular Medicine, Medical University of Graz, Graz, Austria roswitha.pfragner@medunigraz.at.
Medical University of Graz · ATUniversity of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New treatment options are needed for medullary thyroid carcinoma (MTC), a highly metastasizing neuroendocrine tumor that is resistant to standard radiotherapy and chemotherapy. We show that the following shikonin derivatives inhibit cell proliferation and cell viability of the MTC cell line TT: acetylshikonin, β,β-dimethylacrylshikonin, shikonin and a petroleum ether extract of the roots of Onosma paniculata containing several shikonin derivatives. The unsubstituted shikonin derivative was found to be the most effective compound with an IC

Indexed as

apoptosisCAM assaymedullary thyroid carcinomaneuroendocrine tumorshikoninTT cells

Identifiers

PMID28069896
PMCPMC5424774
OpenAlexW2569936112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.